Retatrutide is not yet FDA approved
Each type of drug test has its limitations when it comes to detecting peptides like BPC-157 or IGF-1 LR3, which often require specialized peptide drug screenings
In clinical practice, GHK-Cu is used as a therapeutic peptide , not a beauty product
Read our research peptide safety guide for a broader look at COAs, sterility, vendor transparency, and why injectable research compounds need extra caution
MECHANISM CATEGORIES RESEARCH CONDITIONS SAFETY Side effects Limited human safety data Animal toxicology shows wide therapeutic window Injection-site reactions reported anecdotally Known interactions Anticoagulants (theoretical, due to angiogenic activity unstudied) Contraindications Active malignancy (theoretical, due to angiogenic mechanism) Pregnancy/lactation (unstudied) REGULATORY STATUS FDA Placed on FDA Category 2 of the 503A bulks list (September 2023 update), barring compounding pharmacies from preparing it under section 503A
